Pennsylvania-based West Pharmaceuticals has opened a new manufacturing facility at its Damastown plant in Dublin, adding 330 jobs in a 30% expansion of its Irish workforce. The Irish Times reported on the opening, which brings the company's total Irish workforce to 1,400 across plants in Dublin and Waterford.

The new 165,000 sq ft facility, first announced in November 2024, specialises in high-volume injectable therapies, including medicines for diabetes and weight loss. Novo Nordisk is among the companies that work with West.

West operates a contract services business from the Dublin site, manufacturing packaging and drug delivery systems for a wide range of medicines.

Aileen Ruff-Patry, president of contract manufacturing at West, said: "This expansion increases our global capacity to support drug handling for high-volume injectable therapies, including next-generation GLP-1 treatments. This reinforces West's role as a critical partner in helping to secure patient access to these essential medicines."

The company was not prepared to disclose the size of the investment in its Irish operation. West noted in its 2024 accounts that US tariffs on imports may pose a potential risk to its sales from Ireland to the US market.

Jack Chambers, minister for public expenditure, infrastructure, public service reform and digitalisation, said: "The expansion here has created 330 highly-skilled jobs to meet the increasing global demand for diabetes and obesity treatments, and patient-focused drug delivery solutions."

According to its most recently filed results, West's two Irish operations delivered a pre-tax profit of just under €79 million in 2024, on the back of just under €426 million in sales. The Irish businesses each paid a dividend of more than €60.7 million to their parent company that year.

Read the full story on West Pharmaceuticals' new Dublin manufacturing facility here.